TBX19 CRISPR/Cas9 KO Plasmid (h): sc-406919
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TBX19 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TBX19 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TBX19 CRISPR/Cas9 KO Plasmid (h) | sc-406919 | 20 µg | $397.00 |
Overview
TBX19 (T-box transcription factor 19, also known as TPIT) is a lineage-restricted transcription factor required for specification and maintenance of pituitary corticotroph identity. It regulates gene expression programs that control proopiomelanocortin (POMC) transcription and downstream hypothalamic–pituitary–adrenal axis signaling, integrating with broader T-box–dependent developmental pathways. By shaping endocrine differentiation and hormone-producing cell function, TBX19 is widely used as a marker and mechanistic node in studies of pituitary organogenesis and transcriptional control. Altered TBX19 activity has been linked to disrupted corticotroph function and congenital endocrine phenotypes, supporting its relevance for disease-modeling research on pituitary insufficiency.
TBX19 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TBX19 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TBX19 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TBX19 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TBX19 protein expression.
This CRISPR knockout system enables efficient generation of TBX19-deficient cell models for investigation of TBX19 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TBX19 exon(s) critical for TBX19 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TBX19 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TBX19 CRISPR/Cas9 KO Plasmid (h) and TBX19 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TBX19 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TBX19 HDR Plasmid (h) and TBX19 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TBX19 homology arms to support homology-directed repair at defined TBX19 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.